fda warning letters glp-1 november 2025 Letter Breakdown: Sterility Failures, Subpotent Drugs, and a Compounding Pharmacy Operating Without Control September 15, 2025: Telehealth company

Tirzepatide is a GLP-1 receptor agonist too, but it is also a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist

Johnson & Johnson Johnson & Johnson leverages its extensive healthcare ecosystem to develop and distribute GLP-1 targeted therapies while focusing on patient education and support programs

Medication without metabolic support is incomplete

The odds increase when you simultaneously take oral hormonal birth control pills and Mounjaro during the first four weeks of treatment and four weeks following a dose increase

Rebates are a valuable tool for negotiating price concessions from manufacturers when there are multiple competing products

Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial